Lin CF, Chang YH, Yu FC, et al. - Researchers conducted this nationwide, population-based retrospective cohort study to determine if among patients with non–ST-elevation myocardial infarction (NSTEMI) who received an undefined duration of dual antiplatelet therapy (DAPT), a reduced risk of hospitalization for heart failure (HHF) could be achieved with the implantation of a newer-generation drug-eluting stent (NG-DES) vs that of a bare-metal stent (BMS). The Taiwan's National Health Insurance Research Database was used, and propensity score matching was applied. To assess the risk of HHF in the NG-DES and BMS groups, a competing risk model was created. Findings indicated that risk of HHF may be reduced by NG-DESs in patients with NSTEMI who receive an undefined duration of DAPT.